The results of a phase 2 trial of MSD’s ROR1 inhibitor zilovertamab vedotin (zilo-V) back up the company's decision to push the antibody-drug conjugate (ADC) into a phase 3 programme. Presented at the ...
When Palo Alto officials launched last year an ambitious, $300 million effort to upgrade the city’s electric infrastructure, their plan was to start in residential neighborhoods with overhead wires ...
Total revenue from operations rose by 10.3% to ₹2,326 crore, up from ₹2,109 crore in Q2 FY24.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback